Indel Detection from DNA and RNA Sequencing Data with TransIndel
Overview
Affiliations
Background: Insertions and deletions (indels) are a major class of genomic variation associated with human disease. Indels are primarily detected from DNA sequencing (DNA-seq) data but their transcriptional consequences remain unexplored due to challenges in discriminating medium-sized and large indels from splicing events in RNA-seq data.
Results: Here, we developed transIndel, a splice-aware algorithm that parses the chimeric alignments predicted by a short read aligner and reconstructs the mid-sized insertions and large deletions based on the linear alignments of split reads from DNA-seq or RNA-seq data. TransIndel exhibits competitive or superior performance over eight state-of-the-art indel detection tools on benchmarks using both synthetic and real DNA-seq data. Additionally, we applied transIndel to DNA-seq and RNA-seq datasets from 333 primary prostate cancer patients from The Cancer Genome Atlas (TCGA) and 59 metastatic prostate cancer patients from AACR-PCF Stand-Up- To-Cancer (SU2C) studies. TransIndel enhanced the taxonomy of DNA- and RNA-level alterations in prostate cancer by identifying recurrent FOXA1 indels as well as exitron splicing in genes implicated in disease progression.
Conclusions: Our study demonstrates that transIndel is a robust tool for elucidation of medium- and large-sized indels from DNA-seq and RNA-seq data. Including RNA-seq in indel discovery efforts leads to significant improvements in sensitivity for identification of med-sized and large indels missed by DNA-seq, and reveals non-canonical RNA-splicing events in genes associated with disease pathology.
VISTA: an integrated framework for structural variant discovery.
Sarwal V, Lee S, Yang J, Sankararaman S, Chaisson M, Eskin E Brief Bioinform. 2024; 25(5).
PMID: 39297879 PMC: 11411772. DOI: 10.1093/bib/bbae462.
Improved inference of population histories by integrating genomic and epigenomic data.
Sellinger T, Johannes F, Tellier A Elife. 2024; 12.
PMID: 39264367 PMC: 11392530. DOI: 10.7554/eLife.89470.
Bahrambeigi V, Lee J, Branchi V, Rajapakshe K, Xu Z, Kui N Cancer Res. 2024; 84(10):1719-1732.
PMID: 38451249 PMC: 11096054. DOI: 10.1158/0008-5472.CAN-23-4070.
Relevance of mutation-derived neoantigens and non-classical antigens for anticancer therapies.
Aparicio B, Theunissen P, Hervas-Stubbs S, Fortes P, Sarobe P Hum Vaccin Immunother. 2024; 20(1):2303799.
PMID: 38346926 PMC: 10863374. DOI: 10.1080/21645515.2024.2303799.
Sathapondecha P, Suksri P, Nuanpirom J, Nakkanong K, Nualsri C, Whankaew S Biochem Genet. 2024; 62(6):4396-4407.
PMID: 38306004 DOI: 10.1007/s10528-023-10638-9.